Pierre Feugier

Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials

Maja V. Maraldo, Francesco Giusti, Ivan R. Vogelius et al. · The Lancet Haematology · 2015 · 163 citations

Lymphoid Neoplasia, Cardiovascular Disease, Medicine +4

Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with <scp>non‐Hodgkin</scp> lymphoma treated with B‐cell depleting immunotherapy

Rémy Duléry, Sylvain Lamure, Marc Delord et al. · American Journal of Hematology · 2021 · 156 citations · Full text

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy et al. · Blood · 2022 · 131 citations · Full text

Aggressive B-cell Lymphoma, Immunology, Pathology +18

Human mesenchymal stem cells improve ex vivo expansion of adult human CD34+ peripheral blood progenitor cells and decrease their allostimulatory capacity

Na Li, Pierre Feugier, Brigitte Serrurrier et al. · Experimental Hematology · 2007 · 78 citations

Regenerative Medicine, Ex Vivo Expansion, Cell Therapy +13

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R²) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Franck Morschhauser, Loretta J. Nastoupil, Pierre Feugier et al. · Journal of Clinical Oncology · 2022 · 61 citations · Full text